Media Thread, page-1914

The data that should be ready by August is Her-Vaxx secondary end points for progression free survival.
eg. How long patients are on each arm Her-Vaxx + Chemo vs Chemo only, before their tumor starts to grows again.

The primary outcome for Overall Survival, which will be months if not up to a year away as patients are living longer (really good thing) so not enough patients have passed away to collate and release this data.


@Taureanbull that trial will be the CF33 parent virus called Vaccinia which IMU says is more potent than existing approved Oncolytic virus T-Vec which is only approved for melanoma.
Cf33 CheckVax is less potent as it has a built in PDL1 checkpoint inhibitor and will be the first to be trialed in tripple negative breast cancer and IMU is waiting for the FDA IND approval to start this trial.

Vaccinia they want to do as a basket trial with both inter tumeral and IV injection so it can circulate and hunt out solid cancers and throw everything at it to see what it can kill, remembering that this is the one that pre-clinically killed all 60 NCI lines in testing.

Exciting times ahead while also waiting for updates on PD1-VAX cohort 3 and extension arms.